Cellular senescence perspective of mTOR in the delay of aging process
Abstract
Aging delay is an intricate thing that involves efforts of stress minimization and organism resilience enhancement so that homeostasis can be maintained in order to survive longer in healthy settings. Lately, metformin has become the most common drug used as a pharmacological intervention in both pre-clinical and clinical anti-aging research. Unfortunately, even though metformin research has progressed to clinical trials, the molecular mechanism behind metformin's impact in delaying aging and age-related diseases remains unknown. Countless hypotheses exist regarding the role of mTOR as a crucial gene in the emergence of aging, but there is no systematic explanation that can relate the gene's contribution to modest molecular processes such as cellular senescence, the aging process, and its association with the deceleration provided by metformin. This narrative review discusses the involvement of mTOR in the aging process. Understanding the core molecular pathway of metformin through its primary target gene will help determine the effective dose that provides the maximum slowing effect of aging along with the emphasis on minimum undesirable side effects, both short and long-term.
Keywords: Metformin, mTOR, Cellular senescence, Age-related disease, Aging
How to cite this article:
Citation Formats:
Contact Meral
Meral Publications
www.meralpublisher.com
Davutpasa / Zeytinburnu 34087
Istanbul
Turkey
Email: [email protected]
Tell: +905344998991